Nurix Therapeutics Inc (NASDAQ:NRIX) has a beta value of 2.07 and has seen 1.74 million shares traded in the last trading session. The company, currently valued at $854.60M, closed the last trade at $17.48 per share which meant it gained $3.68 on the day or 26.67% during that session. The NRIX stock price is 7.84% off its 52-week high price of $16.11 and 75.86% above the 52-week low of $4.22. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.82 million shares traded. The 3-month trading volume is 788.10K shares.
Nurix Therapeutics Inc (NASDAQ:NRIX) trade information
Sporting 26.67% in the green in last session, the stock has traded in the green over the last five days, when the NRIX stock price touched $17.48 or saw a rise of 0.17%. Year-to-date, Nurix Therapeutics Inc shares have moved 69.38%, while the 5-day performance has seen it change 17.63%. Over the past 30 days, the shares of Nurix Therapeutics Inc (NASDAQ:NRIX) have changed 17.71%. Short interest in the company has seen 6.41 million shares shorted with days to cover at 5.92.
Nurix Therapeutics Inc (NRIX) estimates and forecasts
Figures show that Nurix Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 145.51% over the past 6 months, with this year growth rate of -23.02%, compared to 13.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -6.70% and -84.40% for the next quarter. Revenue growth from the last financial year stood is estimated to be -10.20%.
10 analysts offering their estimates for the company have set an average revenue estimate of $16.64 million for the current quarter. 10 have an estimated revenue figure of $17.23 million for the next quarter concluding in May 2024.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -59.00% over the past 5 years.
NRIX Dividends
Nurix Therapeutics Inc is expected to release its next earnings report between April 11 and April 15 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Nurix Therapeutics Inc (NASDAQ:NRIX)’s Major holders
Insiders own 2.66% of the company shares, while shares held by institutions stand at 98.59% with a share float percentage of 101.29%. Investors are also buoyed by the number of investors in a company, with Nurix Therapeutics Inc having a total of 182 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 4.52 million shares worth more than $45.15 million. As of Jun 29, 2023, Blackrock Inc. held 9.32% of shares outstanding.
The other major institutional holder is Baker Brothers Advisors, LLC, with the holding of over 3.88 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $38.78 million and represent 8.00% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Total Stock Market Index Fund. As of Sep 29, 2023, the former fund manager holds about 5.30% shares in the company for having 2.57 million shares of worth $20.2 million while later fund manager owns 1.57 million shares of worth $15.7 million as of Jun 29, 2023, which makes it owner of about 3.24% of company’s outstanding stock.
